BARDA

Enhancing the Nation's public health security and emergency preparedness by facilitating communication on innovative products and solutions between federal agencies and public stakeholders

LEARN MORE

ACTIVE OPPORTUNITY SPOTLIGHT

Repurposing and Advancing Innovations Against Rad/Nuc Threats Program

The RePAIR program is the latest step in longstanding efforts to strengthen the nation’s ability to respond to health security threats and is a critical part of BARDA's multi-year strategy. Effective medical countermeasures are needed to reduce severe morbidity and mortality caused by the systemic, multi-organ pathologies of Acute Radiation Syndrome (ARS). Additionally, these medical countermeasures must be available immediately at multiple points of care, such as pharmacies and hospitals, after a radiological or nuclear incident.

LEARN MORE

BARDA Programs

Chemical, Biological, Radiological & Nuclear
(CBRN)

CBRN helps innovators develop promising MCMs from preclinical development to clinical trials and manufacturing scale-up to FDA approval.

CBRN Programs

Antimicrobials
Antivirals & Antitoxins
Burn & Blast MCMs

Chemical MCMs
Radiological & Nuclear MCMs
Vaccines

Learn More

Clinical Development
(DCD)

Providing expert knowledge and support to BARDA’s programs in advanced product development and clinical research, including supporting BARDA clinical studies via the Clinical Studies Network (CSN). Integrated centralized resource: Our focus is BARDA’s success.

Learn More

Contract Management and Acquisition
(CMA)

CMA provides flexible and innovative acquisition solutions in support of BARDA’s mission. CMA strives to enhance the U.S. government’s contracting capabilities to respond quickly to both known and emerging public health threats.

Learn More

Detection, Diagnostics, and Devices Infrastructure
(DDDI)

DDDI invests in diagnostics and devices across the spectrum of advanced research and development, stockpiling, and domestic manufacturing capacity expansion.

Learn More

Nonclinical Development
(DNCD)

DNCD provides nonclinical models, tools, and expertise to advance MCM development. DNCD provides expertise and laboratory capacity to establish and share nonclinical models, conduct appropriate nonclinical studies to support FDA approval, and evaluate potential MCM candidates prior to BARDA investment.

Learn More

Research, Innovation & Ventures
(DRIVe)

DRIVe works to accelerate the development and availability of transformative technologies and approaches to protect Americans from health security threats. DRIVe aims to de-risk the most promising technologies and capabilities.

DRIVe Programs

DRIVe’s R&D Programs

Ecosystem Programs

Learn More

Influenza & Emerging Infectious Diseases
(IEID)

Influenza & EID invests in advanced research and development, manufacturing capacity, and procurement of MCMs to protect the nation from pandemic influenza and other emerging infectious diseases.

Influenza & EID Programs

Pandemic Vaccines and Adjuvants

Therapeutics
Vacccines Development

Learn More

Pharmaceutical Countermeasures and Infrastructure
(PCI)

PCI provides expertise to strengthen the nation’s ability to manufacture, distribute, administer, and scale production of lifesaving MCMs.

Learn More

Regulatory & Quality Affairs
(RQA)

RQA ensures that BARDA-supported MCMs are safe, effective, and in compliance with relevant and current laws, regulations, and guidelines by providing technical expertise and innovative regulatory and policy approaches.

RQA Programs

Regulatory Affairs
Quality Affairs

Regulatory Operations

Learn More

Special Initiatives

BARDA invests in innovative projects across our portfolio, including promising technologies, platforms, and programs. We launch and support efforts designed to accelerate and foster smaller new projects.